



## Phase I/Ib study of olaparib and carboplatin in heavily pretreated recurrent high-grade serous ovarian cancer at low genetic risk

### SUPPLEMENTARY MATERIALS



**Supplementary Figure 1: DNA repair score by progression free survival.** There was no correlation between DNA repair score and PFS. Abbreviations: PFS = progression free survival.



**Supplementary Figure 2: Tissue apoptotic index.** There were no significant differences in tissue apoptotic index before and after cycle 1 treatment with combination therapy of olaparib capsules and carboplatin.

**Supplementary Table 1: 17 Proteins in the original “DNA Repair Score”**

<b>pChk1</b>	<b>ATM</b>
FANCD2	<b>RAD50</b>
MRE11	NBS1
<b>pChk2</b>	<b>MSH2</b>
<b>Chk2</b>	<b>PARP1</b>
<b>pATM</b>	<b>RAD51</b>
<b>XRCC1</b>	BRCA1
<b>53BP1</b>	ATRIP
DNA.PKcs	

Bolded proteins were included in our modified DNA repair score.